Alembic Pharmaceuticals Limited — Q3 FY26
Alembic Pharmaceuticals reported Q3 FY26 revenue of ₹2,876 crore, up 11% YoY, driven by volume expansion and new launches, partially offset by US generics and API pricing pressure.
neutral
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
41%Questions answered4Evaded / deflected11Questions auditedConsistentNumbers vs filing
Answered
High priority
When will India business growth catch up with market growth?
Asked by Damayanti, HSBC
Management gave a specific timeline (Q1 next fiscal) for catching up with market growth.
Read the exchange
Question
So when we are anticipating Olympic India growth to catch up with the market growth and what kind of progress you have seen versus last quarter when we spoke.
Shaun (implied)
I think Q1 of the coming financial year is where we feel we should be back in line with the market growth rate.
Partial answer
Medium priority
What will drive India growth improvement?
Asked by Damayanti, HSBC
Management cited operational execution but gave no specifics on launches or process improvements.
no specific details on launches or process changes
Read the exchange
Question
So whether that will be driven more by improvement in processes or you are looking forward for some meaningful launches etc which can really help you to catch up with the market growth.
Shaun (implied)
I think we're basing this to be more back of operational execution to drive this growth in Q1.
Evasive
High priority
Expectations for upcoming US branded product launch?
Asked by Damayanti, HSBC
Management gave vague optimism but no concrete expectations or reimbursement progress.
no specific reimbursement detailsdeferred to future quarters
Read the exchange
Question
What are your expectation in terms of reimbursement for this product and what preparation are currently underway and what makes you think this will be a success compared to other AMR products?
Pranab (implied)
We believe there's quite a few products already in the market and we can position ourselves well. In terms of efficacy, I think we sit on a sweet spot. Let's take a couple of quarters to see where we stand.
Answered
High priority
When will US business return to growth track?
Asked by Damayanti, HSBC
Management stated US is already growing and gave a specific growth guidance range.
Read the exchange
Question
When these contracts will start appearing in your numbers and when you think US will be back on growth track.
Pranab (implied)
US is already on the growth track as we speak. I expect the US business to grow between 10 to 12% for the full year.
Partial answer
Medium priority
Will R&D spend remain at 65 cr and 9% of revenue next year?
Asked by Candace Pera, Dollar Capital
Management gave a general range but deferred specific guidance for next year.
deferred guidance to next year
Read the exchange
Question
Will it remain in this range for the next year as well for coming 9% of revenue?
Management (unclear)
Next year we will guide sometime when we start the next year. By and large I think we will be between that 8-9% kind of range generally.
Answered
Low priority
How much of other income is forex gain?
Asked by Candace Pera, Dollar Capital
Management provided the exact other income figure and attributed most of it to forex gain.
Read the exchange
Question
If the other income is slightly higher this quarter so is there any forex gain and how much is it?
Management (unclear)
The other income is about 15.5 crores and most of that will be forex gain.
Partial answer
High priority
Why has domestic business growth been tepid for 3-4 years?
Asked by Rahul, IF
Management acknowledged conservatism but gave no concrete steps to address growth.
no specific action planblamed conservatism without quantification
Read the exchange
Question
On the domestic business can you talk about the challenges which we are facing because our domestic business growth has been quite tepid over the past 3 to four years.
Shaun (implied)
I don't think there's a issue of underfunding. Maybe we were too conservative on the doctor spend scenario in the context of UCMP. That's what I understand.
Evasive
Medium priority
Is there need to expand field force in India?
Asked by Rahul, IF
Management gave a non-committal answer with no clear plan on field force expansion.
no commitmentconditional language
Read the exchange
Question
Do you think that there is a need for us to expand a field force in order to drive better penetration at a market level?
Shaun (implied)
I personally don't think at this point we are looking at any further large expansions. But if things start going as per our expectations we would consider.
Deflected
High priority
Will domestic business only grow in line with market or underperform?
Asked by Rahul, IF
Management avoided answering by suggesting an offline conversation.
redirected to offline discussion
Read the exchange
Question
Then our domestic business in the best case scenario would let's say grow only in line with market or continue to slightly underperform market.
Shaun (implied)
I think Rahul we can take this offline. I think it's a lengthier discussion.
Partial answer
High priority
When will US growth pick up from complex opportunities?
Asked by Rahul, IF
Management gave a two-year horizon but no specific growth numbers or milestones.
vague timelineno specific revenue impact
Read the exchange
Question
When do we actually see our US growth picking up from whatever complex opportunities we are pursuing?
Pranab (implied)
Over the next two years is when we should see a lot more of that coming up. We've done a pretty good job and got a lot of market share.
Partial answer
High priority
Can US business grow at mid-teens constant currency in FY27-28?
Asked by Rahul, IF
Management gave a wide range (10-15%) instead of confirming mid-teens, showing uncertainty.
hedged languagewide range given
Read the exchange
Question
Do you think that the US business can grow at a mid-teens kind of a constant currency rate going into 27 and 28?
Pranab (implied)
I would say it's tough for me to say ideally yes I would like to go in the mid-teens but between 10 to 15 at least I would expect the US business to continue growing every year.
Evasive
Medium priority
What margin drag from branded product launch initially?
Asked by Rahul, IF
Management refused to quantify margin impact and suggested waiting, with no concrete guidance.
no specific numbersdeferred to futurevague cushion comment
Read the exchange
Question
With respect to this branded product launch, what kind of a margin drag should we factor in for an initial period till the product starts scaling up?
Pranab and another (unclear)
Till the product starts scaling up there would not we wouldn't have any margin. Let's wait for a couple of quarters. From a modeling perspective you could assume that the margin expansion will be a cushion for the expenses.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| US business to grow 10-12% for full year | 12% | 11% | Matches filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.